# Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

> **NCT00006023** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00006023
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2001-06
- **Final completion:** 2001-06
- **Target enrollment:** — (—)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006023, "Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00006023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*